Current Report Filing (8-k)
May 12 2020 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 12, 2020
SATSUMA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-39041
|
|
81-3039831
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650) 410-3200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
STSA
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02
|
Results of Operations and Financial Conditions.
|
On May 12, 2020, Satsuma Pharmaceuticals, Inc. (Satsuma or the Company) issued a press release
announcing its financial results for the quarter ended March 31, 2020, and its financial position as of March 31, 2020. The full text of the press release is furnished as Exhibit 99.1 hereto.
The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be
deemed filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, or incorporated by reference into any filings of the Company made under the
Securities Act of 1933, as amended, regardless of any general incorporation language in the filing unless specifically stated so therein.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SATSUMA PHARMACEUTICALS, INC.
|
|
|
|
|
Date: May 12, 2020
|
|
|
|
By:
|
|
/s/ Tom ONeil
|
|
|
|
|
|
|
Tom ONeil
|
|
|
|
|
|
|
Chief Financial Officer
|
Satsuma Pharmaceuticals (NASDAQ:STSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Satsuma Pharmaceuticals (NASDAQ:STSA)
Historical Stock Chart
From Sep 2023 to Sep 2024